Indaptus Therapeutics (INDP) Other Accumulated Expenses (2020 - 2026)

Indaptus Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $112350.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 55.95% year-over-year to $112350.0; the TTM figure through Mar 2026 stood at $112350.0 (up 55.95% YoY), while the FY2025 annual figure was $5582.0, down 67.6% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $112350.0, up from $5582.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $112350.0 in Q1 2026, with the low at $5582.0 in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $26110.0 (2024), against an average of $35563.9.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses slumped 99.26% in 2022, then surged 175.92% in 2025.
• Indaptus Therapeutics' Other Accumulated Expenses stood at $29968.0 in 2022, then plunged by 42.17% to $17330.0 in 2023, then retreated by 0.59% to $17228.0 in 2024, then sank by 67.6% to $5582.0 in 2025, then surged by 1912.72% to $112350.0 in 2026.
• Business Quant data shows INDP's Other Accumulated Expenses at $112350.0 in Q1 2026, $5582.0 in Q4 2025, and $19610.0 in Q3 2025.